EGARZO Trademark

Trademark Overview

On Wednesday, August 27, 2014, a trademark application was filed for EGARZO with the United States Patent and Trademark Office. The USPTO has given the EGARZO trademark a serial number of 86378256. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, December 3, 2021. This trademark is owned by Celgene Corporation. The EGARZO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of blood disease, cancer andarthritis
egarzo

General Information

Serial Number86378256
Word MarkEGARZO
Filing DateWednesday, August 27, 2014
Status710 - CANCELLED - SECTION 8
Status DateFriday, December 3, 2021
Registration Number4719820
Registration DateTuesday, April 14, 2015
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 27, 2015

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of blood disease, cancer andarthritis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, December 3, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Friday, December 3, 2021CANCELLED SEC. 8 (6-YR)
Tuesday, April 14, 2020COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, July 28, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 14, 2015REGISTERED-PRINCIPAL REGISTER
Tuesday, January 27, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 27, 2015PUBLISHED FOR OPPOSITION
Wednesday, January 7, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, December 22, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, December 18, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, December 18, 2014EXAMINER'S AMENDMENT ENTERED
Thursday, December 18, 2014NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, December 18, 2014EXAMINERS AMENDMENT E-MAILED
Thursday, December 18, 2014EXAMINERS AMENDMENT -WRITTEN
Tuesday, December 16, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 16, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 16, 2014TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, November 13, 2014NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, November 13, 2014LETTER OF SUSPENSION E-MAILED
Thursday, November 13, 2014SUSPENSION LETTER WRITTEN
Tuesday, October 14, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 14, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 7, 2014TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 23, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 23, 2014NON-FINAL ACTION E-MAILED
Tuesday, September 23, 2014NON-FINAL ACTION WRITTEN
Tuesday, September 23, 2014ASSIGNED TO EXAMINER
Thursday, September 18, 2014PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Tuesday, September 9, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, September 8, 2014ASSIGNED TO LIE
Tuesday, September 2, 2014TEAS VOLUNTARY AMENDMENT RECEIVED
Saturday, August 30, 2014NEW APPLICATION ENTERED IN TRAM

Related Keywords

egarzo pharmaceutical preparations blood treatment cancer andarthritis system disease modulate namely